Identification of the Gene Encoding the Major Latency-associated Nuclear Antigen of the Kaposi’s Sarcoma-associated Herpesvirus

Dean H. Kedes,* Michael Lagunoff,* Rolf Renne,* and Don Ganem†§
*Department of Microbiology and Immunology and †Department of Medicine and the ‡Howard Hughes Medical Institute, University of California Medical Center, San Francisco, California 94143-0414.

Abstract

Over 85% of patients with Kaposi’s sarcoma (KS) are seropositive for antibodies to the latency-associated nuclear antigen (LANA) expressed in B cells lines infected with Kaposi’s sarcoma-associated herpesvirus (KSHV). The presence of antibodies to LANA strongly correlates with the risk of developing the disease. However, the identity of the protein(s) comprising LANA and the corresponding gene(s) has remained unclear. To identify potential latent gene candidates for LANA, we probed total RNA extracted from BCBL-1 cells (a B cell line latently infected with KSHV) using lambda clones that span the KSHV genome. One region encoding latent transcripts spanned KSHV open reading frames (orfs) 71 (K13), 72 (v-cyclin), and 73. Among these, however, only orf 73, when expressed in heterologous mammalian cell systems, reacted with KSHV antibody–positive human sera, resulting in a punctate nuclear staining pattern reminiscent of LANA in BCBL-1 cells. Furthermore, extracts from cells expressing the orf 73 protein product specifically blocked the binding of KS patient antibodies to LANA. Finally, seroreactivity with recombinant orf 73 protein exactly paralleled reactivity with classical LANA as expressed in BCBL-1 cells, both in KS patients and in other groups. Together, these data support the identification of KSHV orf 73 as the gene encoding the dominant immunogenic component of LANA. (J. Clin. Invest. 1997. 100:2606–2610.) Key words: HHV8 • KSHV • Kaposi’s sarcoma

Introduction

Kaposi’s sarcoma–associated herpesvirus (KSHV) also termed human herpesvirus 8 (HHV8), is implicated as a major etiologic agent in the formation of Kaposi’s sarcoma (KS) (1–6), primary effusion lymphomas (PEL; previously known as body cavity-based lymphomas) (7) and a large fraction of cases of multicentric Castleman’s disease (8). Seroepidemiologic and PCR-based studies of patients with these diseases have revealed that viral infection precedes the onset of KS (9–12; D. Kedes and D. Ganem, unpublished findings) and is predictive of an increased risk of tumor development (9, 10, 13, 14). The groups at highest risk of developing KS, namely HIV-positive homosexual men, have the highest KSHV seroprevalence rates (13–16). In contrast, those groups with lower risks of KS development, for example eligible blood donors and even HIV-positive women, intravenous drug users, and hemophiliacs, show correspondingly low rates of seropositivity (13, 14, 16–18). Furthermore, the major route of transmission in nonendemic countries seems to be sexual (13, 15, 16) with its prevalence in homosexual men, for example, rising with greater numbers of sexual partners (J. Martin and D. Kedes, unpublished observations), a known risk factor for KS development (19, 20).

Many of these serologic studies have been based on the detection of antibodies to a latency-associated nuclear antigen (LANA) that is expressed in B cell lines latently infected with KSHV. Infection with KSHV is specifically associated with the development of antibodies to LANA; immunofluorescence assays using sera from infected individuals give a punctate nuclear distribution of LANA in such lines, which are derived from cases of PEL (13, 14, 16). These same sera in Western blots of nuclear extracts from these cell lines react with a high molecular weight polypeptide (11, 16; D. Kedes and D. Ganem, unpublished observations). Seroepidemiologic surveys demonstrate that > 85% of patients with Kaposi’s sarcoma (KS) possess anti-LANA antibodies while only 1–4% of the sera from the general population are positive for such antibodies (13–16).

While these studies presumptively characterize LANA as a viral antigen expressed during the latent phase of infection, they do not specifically identify the viral gene product(s) detected. Since latently expressed genes in other lymphotropic herpesviruses play critical roles in the biology of infection (21), the identification of cognate genes in KSHV is likely to be important in developing a better understanding of the interaction of this virus with its host. In addition, the cloning of the genes for such antigens makes possible the development of second-generation serologic tests for KSHV infection based upon defined recombinant antigens. Here we identify the major component of LANA as the product of the viral open-reading frame (orf) 73.

Methods

Cell culture. COS7, 293 and CV-1 cells were cultured in DME-H16 supplemented with 10% fetal calf serum (LifeTechnologies, Inc., Gaithersburg, MD), 50 μg/ml penicillin and 50 μg/ml streptomycin. Cells were cultured at 37°C in 5% CO₂. BCBL-1 cells were cultured...
as previously described (22). Lytic replication of KSHV in BCBL-1 cells was induced by TPA as described (22).

**RNA extraction and Northern blotting.** BCBL-1 cells were grown to 3 × 10⁷ cells per ml and either left uninduced or induced with 12-O-tetradecanoylphorbol-13-acetate (TPA; 20 ng/ml). 48 h later total RNA from both sets of cells was harvested using RNAzol as recommended by the manufacturer (Tel-Test, Friendswood, TX). Equivalent amounts of RNA were then polyA enriched using the Oligotex protocol (Qiagen, Chatsworth, CA) and separated on a 1% agarose/formaldehyde gel according to standard protocols. The gel was subsequently transferred to bias-N membrane (Amersham International, Buckinghamshire, United Kingdom) and reacted with the appropriate probe as described previously (22). Probes were made by digesting previously isolated lambda clones that encompass 98% of the unique region of the genome (23, 24) with appropriate restriction enzymes, gel purifying specific bands (between 1 and 9 kbp) and radiolabeling using the rediprime protocol (Amersham International). Membranes were exposed to XAR5 film overnight (Eastman Kodak Co., Rochester, NY).

**Patient sera.** Sera collected from KS patients, eligible blood donors, and from women without sexual exposure were described previously (13).

**Cloning of orf 73.** A DNA fragment that included all of orf 73 was recovered from lambda clone 4 (reference 24) after a KpnI/NheI restriction digest. This fragment was ligated into the mammalian expression vector pcDNA3 (Invitrogen, Carlsbad, CA) linearized with KpnI/XbaI. The resulting clone is referred to as pcDNA3-orf 73.

**Transfections.** COS7 cells in log phase growth were transfected with either pcDNA3 or pcDNA3-orf 73 using lipofection with LipofectAMINE (Lifetechologies, Inc.) according to manufacturer's recommendations. Transfection efficiency was evaluated by cotransfecting parallel cultures with either of the pcDNA3-based plasmids containing the lacZ gene. The cell suspension was then sonicated on setting 2 (Sonifer 250; Branson Ultrasonics Corp., Danbury, CT) on ice until nuclei were no longer intact. Adsorbed sera were then used in the IFAs with the appropriate probe as described previously (22). Probes were made by digesting previously isolated lambda clones that encompass 98% of the unique region of the genome (23, 24) with appropriate restriction enzymes, gel purifying specific bands (between 1 and 9 kbp) and radiolabeling using the rediprime protocol (Amersham International). Membranes were exposed to XAR5 film overnight (Eastman Kodak Co., Rochester, NY).

**Immunofluorescence assays (IFA).** Patient sera were diluted with PBS as indicated in the figure legends and then incubated with COS7 cells or with nuclei isolated from BCBL-1 cells as described previously (13). For adsorption experiments, diluted KS and control sera were incubated overnight at 4°C with sonicates from COS7 cells transfected with either pcDNA3 or pcDNA3-orf 73. The final protein concentration in the serum-extract mixes was kept constant (10%, wt/vol). The adsorbed sera were then used in the IFAs with BCBL-1 nuclei. IFAs were visualized by immunofluorescent microscopy (Nikon Microscope-FAX; Nikon Inc., Tokyo, Japan) at a 600-fold magnification. Photographs were taken with Kodachrome 400 ASA film (Eastman Kodak Co.).

### Results

The phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) induces a marked increase in the transcription of the lytic genes in cultured cells latently infected by many lymphotropic herpesviruses, including KSHV (22, 26). Without such stimulation, these transcripts are present at very low or negligible levels. In contrast, transcripts of many latent viral genes are expected to be present in the absence of TPA induction. Exploiting this difference, we attempted to identify regions of the KSHV genome encoding potential latent gene products by screening for regions actively transcribed in the absence of TPA. We reasoned that this process would narrow the choices of potential candidate genes that could encode the latency-associated nuclear antigen (LANA) that we and others previously identified by IFA (13, 14).

Accordingly, we prepared RNA from BCBL-1 cells grown in the presence or absence of TPA and examined this RNA for viral gene expression by Northern blotting, using as probes a number of large viral DNA fragments from across the 170-kb viral genome (24). As shown in Fig. 1 (lanes I and 2) one clone (lambda 4-3) revealed the presence of viral transcripts that were of nearly equal abundance in both uninduced and induced cultures, strongly suggesting that this clone harbors latently expressed viral genes. DNA sequencing revealed that this clone spans KSHV orf 73, 72, and 73 (detailed analyses of the transcripts and their promoters from this region will be published elsewhere; Dirk Dittmer and D. Ganem, manuscript in preparation). In contrast, most other clones tested revealed a marked increase in the levels of transcripts, consistent with lytically expressed viral genes. Fig. 1 (lanes 3 and 4) demonstrate an example of this latter pattern with a probe from lambda clone 13-3 (reference 24) encompassing the glycoprotein M homolog (27). Of course, inducibility by TPA does not preclude the possibility of latent gene expression: for example, any latent gene which continues to be transcribed during the lytic cycle would show transcriptional activity as a result of DNA copy number amplification. It is therefore highly likely that additional latent genes exist outside of the region encompassed by lambda 4-3.

To determine which (if any) of the orfs 71–73 might encode LANA, we then subcloned each of these three orfs into mammalian expression vectors. The resulting clones were then

---

**Figure 1.** Northern analysis of uninduced and TPA-induced BCBL-1 cells. PolyA-enriched RNA from uninduced and TPA-induced BCBL-1 cells was separated on an agarose/formaldehyde gel, transferred to a nylon membrane, reacted with a radiolabeled probe, and exposed to Kodak XAR5 film overnight. The probe for lanes 3 and 4 was generated by radiolabeling a Sall restriction fragment (~4.5 kbp) from lambda 4 (reference 24) which contains orf 72 and 73 and part of ORF 71 (K13). The probe for lanes 3 and 4 was generated by radiolabeling the fourth largest Sall fragment (~2 kbp) from lambda 13 (reference 24) which contains the region around orf 38 and 39 (glycoprotein M homolog) (27).
transfected individually into COS7 cells and, 2 d later, the monolayers were assayed by immunofluorescence using KS patient antisera known to be positive for anti-LANA antibodies in high titer. Cells transfected with the orf 71 and 72 expression vectors gave no discernible immunofluorescence signal in this assay, despite efficient transfection, as judged by β-galactosi-
locus bearing several genes whose transcriptional pattern strongly suggests that they encode latent gene products. In Epstein-Barr virus infection, latently expressed viral genes play several key roles, including maintenance of the viral episomal replicon (a function central to viral persistence) and transactivation of a number of host and viral genes involved in the deregulation of cellular physiology and growth (21). Like LANA of KSHV, several of these EBV proteins were initially recognized as nuclear antigens reactive with patient antisera in immunofluorescence assays. In view of these precedents, and since anti-LANA antibodies provide the first visualization of a latent KSHV gene product, the molecular identification of LANA is of some importance.

Our data demonstrate that LANA is comprised predominantly of a single viral protein, encoded by orf 73 of the KSHV genome. Expression of this gene in transient assays results in accumulation of a nuclear antigen reactive with anti-LANA antisera, and authentic anti-LANA reactivity can be completely adsorbed by cell extracts bearing orf 73 as their sole viral protein. In addition, the pattern of serologic reactivity to recombinant orf 73 protein in several patient groups closely mirrors that observed in the canonical LANA assay, leaving no doubt about the assignment of the orf 73 product as the antigen responsible for LANA reactivity. The pattern of antibody staining of recombinant orf 73 shows minor differences in the size and number of the punctate speckles from that observed in LANA expressed in latently infected B cells. These differences may be due, in part, to the overexpression of the orf 73 protein, an interpretation supported by the fact that punctate staining is more evident in COS7 cells expressing lower levels of the protein. However, we do not exclude the possibility that other host or viral proteins could influence the intranuclear distribution of orf 73 protein.

The identification of orf 73 as LANA opens the way to further explorations of its function(s) in the latent infection. Examination of the predicted primary amino acid sequence of the orf 73 product reveal it to be a large polypeptide with numerous repeated blocks of acidic residues; similar domains often function in transcriptional activation in other viral and host proteins (28). In addition, the protein contains sequences compatible with potential coiled–coil domains, elements known to mediate homo- and heterooligomerization. Both of these features are found in proteins involved in the regulation of gene expression, and recall similar features of EBNA-2, a major la-

Figure 3. Orf 73 containing COS7 cell sonicates block KSHV (anti-LANA) antibodies. A KS patient serum with an anti-LANA IFA titer of over 1:3,200 was diluted to 1:200 and preadsorbed with sonicates from COS7 cells transfected with vector alone (A); a mixture of sonicates from COS7 cells transfected with either pcDNA3-orf 73 or pcDNA3 in a ratio of 1:3 (B) or 1:1 (C). Preadsorption with sonicate exclusively from cells transfected with pcDNA3-orf 73 is shown in (D). The total protein from sonicates added in (A–D) was identical.
Concordance of LANA (BCBL-1 nuclei) and orf 73 protein (COS7 cells) IFAs in the detection of KSHV antibodies in different populations. Numbers in parentheses are the total number of subjects in each group. The positive (+) and negative (−) signs signify the results of the IFAs. All sera were diluted 1:10.

<table>
<thead>
<tr>
<th>Group</th>
<th>BCBL-1 (LANA)</th>
<th>COS7-orf 73</th>
<th>Concordance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low risk women (18)</td>
<td>0 18</td>
<td>0 18</td>
<td>100</td>
</tr>
<tr>
<td>Blood donors (50)</td>
<td>0 50</td>
<td>0 50</td>
<td>100</td>
</tr>
<tr>
<td>KS patients (33)</td>
<td>29 4</td>
<td>29 4</td>
<td>100</td>
</tr>
</tbody>
</table>

Note added in proof: Subsequent to the submission of this manuscript, Rainbow et al. have published the finding that orf 73 encodes a high molecular weight protein doublet that is present in another KSHV-infected cell line and that reacts with KS patient sera in both Western analyses and indirect immunofluorescence assays (29).